Core Viewpoint - Langzi Co., Ltd. has shown a significant increase in stock price, reaching 19.94 CNY per share with a market capitalization of 8.822 billion CNY, indicating strong investor interest and trading activity [1]. Company Overview - Langzi Co., Ltd. was established on November 9, 2006, and went public on August 30, 2011. The company is based in Chaoyang District, Beijing, and specializes in the design, production, and sales of branded women's clothing [1]. - The main revenue composition of Langzi includes: non-surgical medical beauty (41.59%), women's skirts (11.34%), women's tops (11.22%), children's clothing (10.90%), women's outerwear (9.55%), surgical medical beauty (6.21%), children's products (4.70%), women's pants (3.31%), and others (1.18%) [1]. Shareholder Information - Among the top ten circulating shareholders of Langzi, a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 24,300 shares in the third quarter, now holding 2.021 million shares, which accounts for 0.79% of the circulating shares [2]. - The Southern CSI 1000 ETF has a total scale of 76.63 billion CNY and has achieved a year-to-date return of 27.12%, ranking 2130 out of 4216 in its category [2]. Fund Management - The fund manager of Southern CSI 1000 ETF is Cui Lei, who has been in the position for 6 years and 360 days. The total asset scale under management is 122.76 billion CNY, with the best fund return during the tenure being 182.39% and the worst being -15.93% [3].

Core Viewpoint - The major shareholder, Langzi Co., Ltd., has completed its share reduction plan for Ruoyuchen Technology Co., Ltd., reducing its stake to approximately 4.36% and officially exiting the list of significant shareholders holding over 5% [1] Group 1: Shareholding Changes - Langzi Co., Ltd. reduced its holdings in Ruoyuchen from over 5% to 4.36%, retaining 13.55 million shares [1] - Langzi Co., Ltd. initially acquired a 20% stake in Ruoyuchen in 2015 for 110 million yuan [2] - Since September 2022, Langzi Co., Ltd. has been continuously reducing its holdings, cashing out nearly 500 million yuan by September 2025 [2] Group 2: Financial Performance - In the first half of 2025, Langzi Co., Ltd. reported a net profit of 274 million yuan, a year-on-year increase of 64.09%, but the profit excluding gains from share reductions was only 136 million yuan, a decrease of 2.70% [2] - Revenue from Langzi Co., Ltd.'s medical beauty business in the first half of 2025 was 1.333 billion yuan, down 6.1% year-on-year, with significant reliance on its Milan Baiyu brand [2] Group 3: Business Operations and Challenges - Langzi Co., Ltd. is actively pursuing acquisitions in the medical beauty sector, recently announcing a cash acquisition of 67.5% of Chongqing Milan Baiyu Shiguang Medical Beauty Hospital for 92.475 million yuan [3] - The company faces significant financial pressure, with short-term loans increasing from 684 million yuan at the beginning of 2024 to 1.314 billion yuan by year-end [4] - Langzi Co., Ltd. is required to pay back taxes and penalties totaling approximately 30.82 million yuan, which is expected to reduce the company's net profit for 2025 by about 3.082 million yuan, representing 15% of the projected net profit for 2024 [4]

证券代码：003010 证券简称：若羽臣 公告编号：2025-017 广州若羽臣科技股份有限公司 回购报告书 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 上述风险可能导致本次回购计划无法顺利实施，回购方案实施过程中出现前述风险情 形的，公司将及时履行信息披露义务并说明拟采取的应对措施。敬请投资者注意投资风险。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券 法》《上市公司股份回购规则》（以下简称"《回购规则》"）《深圳证券交易所上市公 司自律监管指引第9号——回购股份》（以下简称"《回购指引》"）以及《公司章程》 等相关规定，公司编制了《回购报告书》，具体内容如下： 1、广州若羽臣科技股份有限公司（以下简称"公司"、"若羽臣"或"本公司"） 于2025年2月19日召开第四届董事会第五次会议，审议通过了《关于2025年度第一期回购 公司股份方案的议案》，根据《公司章程》的相关规定，公司本次回购方案经三分之二以 上董事出席的董事会会议决议通过即可，无需提交股东大会审议。 2、公司使用自有资金和股票回购专项贷款资金通过 ...